Literature DB >> 28460251

Streptococcus pneumoniae-induced ototoxicity in organ of Corti explant cultures.

Michael Perny1, Magdalena Solyga2, Denis Grandgirard3, Marta Roccio2, Stephen L Leib4, Pascal Senn5.   

Abstract

Hearing loss remains the most common long-term complication of pneumococcal meningitis (PM) reported in up to 30% of survivors. Streptococcus pneumoniae have been shown to possess different ototoxic properties. Here we present a novel ex vivo experimental setup to examine in detail the pattern of hair cell loss upon exposure to different S. pneumoniae strains, therefore recapitulating pathogen derived aspects of PM-induced hearing loss. Our results show a higher susceptibility towards S. pneumoniae-induced cochlear damage for outer hair cells (OHC) compared to inner hair cells (IHC), which is consistent with in vivo data. S. pneumoniae-induced hair cell loss was both time and dose-dependent. Moreover, we have found significant differences in the level of cell damage between tissue from the basal and the apical turns. This shows that the higher vulnerability of hair cells located at high frequency regions observed in vivo cannot be explained solely by the spatial organisation and bacterial infiltration from the basal portion of the cochlea. Using a wild type D39 strain and a mutant defective for the pneumolysin (PLY) gene, we also have shown that the toxin PLY is an important factor involved in ototoxic damages. The obtained results indicate that PLY can cause both IHC and OHC loss. Finally, we are reporting here for the first time a higher vulnerability of HC located at the basal and middle cochlear region to pneumolysin-induced damage. The detailed description of the susceptibility of hair cells to Streptococcus pneumoniae provided in this report can in the future determine the choice and the development of novel otoprotective therapies during pneumococcal meningitis.
Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hair cells; Organ of Corti; Ototoxicity; Pneumolysin; Streptococcus pneumoniae

Mesh:

Substances:

Year:  2017        PMID: 28460251     DOI: 10.1016/j.heares.2017.04.012

Source DB:  PubMed          Journal:  Hear Res        ISSN: 0378-5955            Impact factor:   3.208


  6 in total

1.  Combining Ceftriaxone with Doxycycline and Daptomycin Reduces Mortality, Neuroinflammation, Brain Damage, and Hearing Loss in Infant Rat Pneumococcal Meningitis.

Authors:  Lukas Muri; Michael Perny; Jonas Zemp; Denis Grandgirard; Stephen L Leib
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

Review 2.  In vitro and in vivo models: What have we learnt about inner ear regeneration and treatment for hearing loss?

Authors:  Mary P Lee; Joerg Waldhaus
Journal:  Mol Cell Neurosci       Date:  2022-05-14       Impact factor: 4.626

3.  Cortex Cercis chinensis Granules Attenuate Streptococcus pneumoniae Virulence by Targeting Pneumolysin.

Authors:  Yan Xu; Yanbo Wang; Yinan Guo; Lina Wei; Lizhong Ding; Zhongtian Wang; Liping Sun
Journal:  Evid Based Complement Alternat Med       Date:  2020-06-16       Impact factor: 2.629

4.  Near-infrared-light pre-treatment attenuates noise-induced hearing loss in mice.

Authors:  Dietmar Basta; Moritz Gröschel; Ira Strübing; Patrick Boyle; Felix Fröhlich; Arne Ernst; Rainer Seidl
Journal:  PeerJ       Date:  2020-06-17       Impact factor: 2.984

5.  Combined effect of non-bacteriolytic antibiotic and inhibition of matrix metalloproteinases prevents brain injury and preserves learning, memory and hearing function in experimental paediatric pneumococcal meningitis.

Authors:  Lukas Muri; Denis Grandgirard; Michelle Buri; Michael Perny; Stephen L Leib
Journal:  J Neuroinflammation       Date:  2018-08-21       Impact factor: 8.322

Review 6.  MMPs and ADAMs in neurological infectious diseases and multiple sclerosis.

Authors:  Lukas Muri; David Leppert; Denis Grandgirard; Stephen L Leib
Journal:  Cell Mol Life Sci       Date:  2019-06-06       Impact factor: 9.261

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.